乌鸦传媒

<乌鸦传媒 class='mpt-top_cat_title'>Neurology >

Multiple Sclerosis

News, opinions and meeting coverage in neurology.

<乌鸦传媒>New Hints that Vitamin D Helps MS Patients

Two randomized trials miss endpoints but still strongly suggest benefit

<乌鸦传媒>Is 'No Evidence of Disease Activity' a Misnomer in MS?

Many patients still show signs of active disease despite meeting current NEDA criteria

<乌鸦传媒>'This is a Quadfecta!' What We Heard This Week

Quotable quotes from 乌鸦传媒's sources

<乌鸦传媒>FDA Again Warns on Balloon Angioplasty for Neurologic Disorders

Says transvascular autonomic modulation is off-label and dangerous

<乌鸦传媒>Fatigue, Leg Dysfunction Predict Multiple Sclerosis Progression

Both associated with subsequent conversion to secondary progressive MS

<乌鸦传媒>European MS Guidance Taking Shape

ECTRIMS teases the first-ever MS drug guideline

<乌鸦传媒>Remyelinating Drug Flops in MS

Large placebo response, 'inverted U-shaped' dose-response in phase II trial

<乌鸦传媒>Registry Data: Lemtrada More Effective than Competing MS Tx

Better than fingolimod or interferon; comparable to natalizumab

<乌鸦传媒>New Ampyra Trial Bolsters MS Efficacy Claims

Walking ability, as reported by patients, significantly improved

<乌鸦传媒>Fluoxetine Flops as Progressive MS Therapy

Trial may have been underpowered to detect a benefit

<乌鸦传媒>Rituximab Bests MS Drugs in Swedish Registry

Rituximab offered drug survival advantage over fingolimod, natalizumab

<乌鸦传媒>HIV Drug Fails in Small MS Trial

Casts doubt on novel theory of MS etiology

<乌鸦传媒>Home-Based DVD May Motivate Seniors With MS to Exercise

Patients reported improvements in physical fitness, self-confidence

<乌鸦传媒>Studies Try to Estimate MS Drug Prices

Meds are expensive but push other costs down

<乌鸦传媒>Lemtrada Offers Long-Term Stability in MS Patients

Mean change in EDSS score was only +0.06

<乌鸦传媒>Lymphopenia Risk Factors to Watch With DMF

Age, race, baseline lymphocytes, overweight, & vitamin D levels included

<乌鸦传媒>Tysabri No Help in SPMS

Drug didnt reduce disability progression but may benefit upper limb function

<乌鸦传媒>Novel Drug Bests Interferon at Halting MS Activity

Nearly half of patients on ocrelizumab achieved no evidence of disease activity (NEDA)

<乌鸦传媒>Biogen Reports Another Tecfidera PML Case

Non-fatal case is the second one for the oral MS drug.

<乌鸦传媒>Novel MS Drug Offers Good Functional Outcomes

Daclizumab HYP beats interferon for patient-centered outcomes

<乌鸦传媒>No Surprises with Tysabri-Tecfidera Switch

Discontinuation rates for both agents were in line with those seen in clinical trials

<乌鸦传媒>Ballroom Dance a Boon to MS Patients

A small study finds ballroom dance -- waltz, salsa, foxtrot, and others -- may improve function in MS patients.

<乌鸦传媒>Does a Cocktail a Day Keep MS Symptoms at Bay?

Patients consuming more of the hard stuff had lower EDSS scores.

<乌鸦传媒>Seizure Drug May Help in MS Eye Disease

Phenytoin shows promise for slowing neurodegeneration in optic neuritis.

<乌鸦传媒>An 80-Proof Antidote for MS Disability?

Patients consuming more of the hard stuff had lower EDSS scores.

<乌鸦传媒>Increasing Tysabri Dosing Interval May Cut PML Risk

No sacrifice of efficacy seen in retrospective analysis.

<乌鸦传媒>Novel Drug for Cramping Shows Promise in Early Trial

Could benefit patients with MS spasticity and cervical dystonia.

<乌鸦传媒>Skull Size Tied to Disability Risk in MS

BOSTON -- Multiple sclerosis patients with larger intracranial volumes -- a measure of their lifetime maximal brain size -- scored better on cognition and physical function tests than those with smaller skull sizes.

<乌鸦传媒>Multiple Sclerosis Risk Tied to Some OCs

BOSTON -- Women using combined oral contraceptives containing norethindrone or levonorgestrel were substantially more likely to develop multiple sclerosis than those not on "The Pill."

<乌鸦传媒>Generic Copaxone for MS Passes Clinical Test

BOSTON -- A copycat version of the multiple sclerosis drug Copaxone, known generically as glatiramer acetate, performed similarly to the original product in a head-to-head trial, paving the way for it to win regulatory approval as a generic drug.

<乌鸦传媒>Novel Drug Beats Avonex for MS Efficacy; Safety Still a Worry

BOSTON -- Daclizumab HYP cut relapse rates and disability progression in multiple sclerosis patients more effectively than interferon beta-1a (Avonex) in a phase III trial, but liver toxicity with the IL-2 inhibitor reared its head again.

<乌鸦传媒>Dalfampridine: Not Just a Walking Aid

DALLAS -- Extended-release dalfampridine (Ampyra) is approved for boosting walking speed in multiple sclerosis patients, but its benefits extend to other aspects of physical function, according to a small study reported here.

<乌鸦传媒>CCSVI Practices Suboptimal but Patients Don't Mind

DALLAS -- Canadian multiple sclerosis patients who left the country to undergo the controversial procedure called chronic cerebrospinal venous insufficiency (CCSVI) often received poor pre- and postoperative care, but most were still relatively satisfied overall, a researcher reported here.

<乌鸦传媒>Gastro Effects Dog Oral MS Drug Tecfidera

DALLAS -- Large proportions of patients starting on dimethyl fumarate (Tecfidera) for multiple sclerosis need additional medications to manage the drug's GI and other side effects, and a substantial minority ultimately find the drug intolerable.

<乌鸦传媒>MS Bladder Problems Show Up Early and Often

Nearly 80% of multiple sclerosis patients in a large registry reported overactive bladder symptoms, and one-third of a separate cohort of newly diagnosed patients also showed urinary dysfunction, researchers reported here.

<乌鸦传媒>Striking a Nerve: MS Cured With an OTC Drug?

A neurology researcher is planning a clinical trial of a widely available drug that he thinks could stave off disability in multiple sclerosis patients. How much should he (or we) say publicly about it?

<乌鸦传媒>Repeat Botox OK for Urinary Incontinence in MS Patients

COPENHAGEN -- Long-term treatment with serial onabotulinum toxin A (Botox) of urinary incontinence among multiple sclerosis (MS) patients appeared to be safe and effective, researchers reported here.

<乌鸦传媒>PML Not Fatal if Caught Early

SAN DIEGO - All multiple sclerosis patients taking natalizumab (Tysabri) who were diagnosed with a serious condition called PML before symptoms appeared were still alive a year later, researchers said.

<乌鸦传媒>New Guideline on Transverse Myelitis Released

Certain clinical, imaging, and laboratory findings can help determine the etiology and prognosis in patients presenting with transverse myelitis, according to a new guideline from the American Academy of Neurology.

<乌鸦传媒>MS Walking Drug Gets FDA Nod

WASHINGTON -- The FDA approved the first drug for improved walking in patients with multiple sclerosis, the tablet dalfampridine (Ampyra).

鈥�

6